Swiss biopharmaceutical firm NLS Pharmaceutics faces Nasdaq delisting due to failing to maintain a $1 per share bid price.

Swiss biopharmaceutical firm NLS Pharmaceutics received a delisting determination from Nasdaq due to failing to maintain a $1 per share bid price over 30 consecutive business days. The company plans to request a hearing before a Nasdaq Hearings Panel to discuss a compliance plan and request an extension. However, there's no guarantee the panel will grant the extension or that the company will ultimately regain compliance.